Longitudinal Multicenter Susceptibility Trends of Ceftazidime/Avibactam and Imipenem/Relebactam and Dose Optimization in Critically Ill Patients with Carbapenem-Resistant Enterobacterales Bloodstream Infections
Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-14
DOI: 10.2147/dddt.s646095 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Xueting Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore B…. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Ceftazidime, Imipenem, Anti-Bacterial Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Developme…
- Peking Union Medical College & Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Research Units of Infectious Disease and Microecology, Chinese Academy of Medical Sciences, Beijing, People's Republic…
- Department of Structure and Morphology, Jinan Microecological Biomedicine Shandong Laboratory, Jinan, People's Republic of China.
- Department of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, People's Republic of China.
- Department of Respiratory Medicine, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
ORCID-Profile: Pan Chen, Yunbo Chen, Jinru Ji, Chaoqun Ying, Zhiying Liu, Yonghong Xiao
Zitieren
APA
Wang, X., Chen, P., Chen, T., Xiong, L., Yi, Z., Chen, Y., Shen, P., Ji, J., Ying, C., Liu, Z., & Xiao, Y. (2026). Longitudinal Multicenter Susceptibility Trends of Ceftazidime/Avibactam and Imipenem/Relebactam and Dose Optimization in Critically Ill Patients with Carbapenem-Resistant Enterobacterales Bloodstream Infections. Drug Design, Development and Therapy, Volume 20, 1-14. https://doi.org/10.2147/dddt.s646095
Vancouver
Wang X, Chen P, Chen T, Xiong L, Yi Z, Chen Y, et al. Longitudinal Multicenter Susceptibility Trends of Ceftazidime/Avibactam and Imipenem/Relebactam and Dose Optimization in Critically Ill Patients with Carbapenem-Resistant Enterobacterales Bloodstream Infections. Drug Design, Development and Therapy. 2026;Volume 20:1-14. doi:10.2147/dddt.s646095
BibTeX
@article{Wang2026,
author = {Wang, Xueting and Chen, Pan and Chen, Tao and Xiong, Luying and Yi, Zijian and Chen, Yunbo and Shen, Ping and Ji, Jinru and Ying, Chaoqun and Liu, Zhiying and Xiao, Yonghong},
title = {Longitudinal Multicenter Susceptibility Trends of Ceftazidime/Avibactam and Imipenem/Relebactam and Dose Optimization in Critically Ill Patients with Carbapenem-Resistant Enterobacterales Bloodstream Infections},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--14},
doi = {10.2147/dddt.s646095}
}
EUVIMED